Hollow Prussian Blue Nanoparticle-Based Controlled-Release Nanocapsules for Enhanced Tumor Antiangiogenesis Therapy

Angiogenesis is a fundamental step for the development of malignant tumors, where neovascularization provides oxygen and nutrients to tumor cells. Besides this, these newly formed blood vessels also offer a pathway for tumor cells to enter the bloodstream, promoting tumor dissemination and metastasis. Therefore, antiangiogenic therapy has emerged as an effective strategy for malignant tumor treatment. However, traditional antiangiogenic agents face several limitations in clinical applications, including lack of specific targeting, significant systemic toxicity, and suboptimal therapeutic outcomes. In this work, we developed a near-infrared light (NIR)-triggered photothermal controlled-release nanocapsule designed to enhance antiangiogenesis therapy for triple-negative breast cancer. For photothermal controlled release, the nanocapsule was constructed by FDA-approved photothermal therapy agents, specifically, hollow Prussian blue nanoparticles, and loaded with an FDA-approved photosensitizer, indocyanine green. To prevent burst release, polydopamine was used to encapsulate the antiangiogenic drug-loaded nanoparticles. To endow the tumor accumulation, hyaluronic acid was finally modified on the surface of the nanocapsule. This nanocapsule can accumulate in the tumor site and locally controlled-release drug programmed by NIR, which achieved spatial and temporal controlled release of the antiangiogenic drug, overcoming adverse effects and enhancing the treatment efficiency of antiangiogenesis therapy.